Medical Oncology

Medicine & Life Sciences

1. Gastrointestinal Stromal Tumors 100%
2. Endoscopic Ultrasound-Guided Fine Needle Aspiration 70%
3. Neoplasms 65%
4. Sunitinib 64%
5. TAS-116 57%
6. Imatinib Mesylate 56%
7. Neoplastic Stem Cells 53%
8. Drug Therapy 53%
9. fosaprepitant 46%
10. Neoplasm Metastasis 43%
11. Japan 42%
12. XELOX 40%
13. Meglumine 40%
14. Cisplatin 40%
15. Colorectal Neoplasms 39%
16. Safety 39%
17. regorafenib 39%
18. Aprepitant 37%
19. Vinorelbine 33%
20. HSP90 Heat-Shock Proteins 32%
21. Therapeutics 32%
22. Pemetrexed 32%
23. Breast Neoplasms 31%
24. Omentum 30%
25. Small Cell Carcinoma 30%
26. Leiomyosarcoma 29%
27. Return to Work 29%
28. Neuroendocrine Tumors 28%
29. Carboplatin 28%
30. Paclitaxel 27%
31. Eastern Europe 26%
32. Radiotherapy 25%
33. Stomach Neoplasms 25%
34. South America 24%
35. Pancreatitis 24%
36. Pancreatic Neoplasms 23%
37. Drug-Related Side Effects and Adverse Reactions 23%
38. Breast 22%
39. Nausea 22%
40. Progression-Free Survival 21%
41. Vomiting 21%
42. Pancreas 21%
43. Confidence Intervals 21%
44. Heterografts 20%
45. Hypersensitivity 20%
46. Organoids 19%
47. Differential Diagnosis 19%
48. Thrombosis 19%
49. Systematic Reviews 18%
50. Up-Regulation 18%
51. Obesity 17%
52. Modified Radical Mastectomy 17%
53. Placebos 17%
54. Cohort Studies 17%
55. Survival 16%
56. Thoracic Wall 16%
57. Radiation Dosage 16%
58. Epirubicin 15%
59. Korea 15%
60. Incidence 15%
61. Epithelial Cell Adhesion Molecule 14%
62. Adjuvant Chemotherapy 14%
63. Point Mutation 14%
64. Antibodies 13%
65. Kidney 13%
66. Etoposide 13%
67. Literature 13%
68. Genes 13%
69. Population 13%
70. Creatinine 12%
71. Head and Neck Neoplasms 12%
72. Selection Bias 12%
73. MicroRNAs 12%
74. Body Mass Index 11%
75. Cyclophosphamide 11%
76. Disease Progression 11%
77. Myoma 10%
78. Staining and Labeling 10%
79. Recurrence 10%
80. Malignant Mesothelioma 10%
81. Thymoma 10%
82. Pancreatectomy 9%
83. Desmin 9%
84. Lung Neoplasms 9%
85. Loss of Function Mutation 9%
86. Bone Marrow 9%
87. Leiomyoma 9%
88. Liver 9%
89. Capecitabine 8%
90. Hematologic Tests 8%
91. Cell Nucleus 8%
92. pembrolizumab 8%
93. Hysterectomy 8%
94. Gene Frequency 8%
95. Nivolumab 8%
96. Genetic Variation 8%
97. Introns 8%
98. Computer Simulation 7%
99. Bevacizumab 7%
100. Antineoplastic Agents 7%